pharma news today obesity drugs glp-1 october 2025 Drugmakers are racing to find the next Wegovy. These trials are ones to watch Real-world studies of GLP-1 discontinuation

Shop Energy-Efficient Appliances in Athens If your refrigerator or other appliances are outdated, upgrading to energy-efficient models can make a huge difference year-roundnot just during vacations

In a multi-agonist framework, these effects may complement the weight-loss and insulin-sensitizing effects of GLP-1 and GIP receptor activation

Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: a systematic review and meta-analysis

Liu, L., Cui, Y., Chang, Y

Advertised products included semaglutide (92/93), tirzepatide (40/93), liraglutide (2/93), and retatrutide (1/93)

Some PK studies report an increased theoretical risk of toxicity with advancing age [62,63,64,65,66,67] due to prolongation of t 1/2 [62, 63], reduced paracetamol clearance [64, 67], increased paracetamol oxidation caused by a reduction in glucuronidation and sulphation capacity [65] or a reduction in liver volume [66]